SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (1274)6/29/2004 1:21:00 AM
From: charlyt   of 1298
 
Not too surprising I guess. A very difficult patient population to treat.

The phase 2 trial in patients that can have the tumor surgically removed is the one to watch given the phase 1 results. Despite surgical intervention, there is a medical need in this population. Median survival after surgery is 15-19 months with 5-year survival of 20% according to NCCN: nccn.org

PR says data possibly in '05. Given their track record on timelines probably ASCO '06 is more likely. Even if it works, still a long way to go to get on the market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News